よむ、つかう、まなぶ。
10参考資料１－２ 成人用肺炎球菌ワクチンファクトシート［4.9MB］ (40 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_70339.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会（第64回 2／12）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
99.
MSD 株式会社. 添付文書 15 価肺炎球菌結合型ワクチン「バクニュバンス®水性懸濁注シリンジ」.
2024.
100.
ファイザー株式会社. 添付文書プレベナー20 水性懸濁注. 2024.
101.
Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-
polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9(3): 213-20.
102.
Papadatou I, Tzovara I, Licciardi PV. The Role of Serotype-Specific Immunological Memory in
Pneumococcal Vaccination: Current Knowledge and Future Prospects. Vaccines (Basel) 2019; 7(1).
103.
森野紗衣子, 神谷元, 常彬, 明田幸宏. 今後期待される新規肺炎球菌ワクチン. IASR 2023.
104.
Klugman KP. Vaccines. 7th ed. Philadelphia: Saunders; 2018.
105.
独立行政法人医薬品医療機器総合機構. ニューモバックス NP 審議結果報告書. 2006.
https://www.pmda.go.jp/drugs/2006/P200600040/63015300_21800AMY10131_A100_1.pdf (accessed
2025/1/20).
106.
独立行政法人医薬品医療機器総合機構. 沈降 15 価肺炎球菌結合型ワクチン（無毒性変異ジフテリア
毒素結合体）審議結果報告書. 2023.
https://www.pmda.go.jp/drugs/2023/P20230606001/170050000_30400AMX00410_A100_1.pdf (accessed
2025/1/20).
107.
独立行政法人医薬品医療機器総合機構. プレベナー20 審議結果報告書. 2024.
https://www.pmda.go.jp/drugs/2024/P20240829003/672212000_30600AMX00115_A100_2.pdf (accessed
2025/1/20).
108.
Ermlich SJ, Andrews CP, Folkerth S, et al. Safety and immunogenicity of 15-valent pneumococcal
conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. Vaccine 2018; 36(45): 6875-82.
109.
Peterson JT, Stacey HL, MacNair JE, et al. Safety and immunogenicity of 15-valent pneumococcal
conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously
vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother 2019; 15(3): 540-8.
110.
Platt HL, Cardona JF, Haranaka M, et al. A phase 3 trial of safety, tolerability, and immunogenicity of
V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in
adults 50 years of age and older (PNEU-AGE). Vaccine 2022; 40(1): 162-72.
111.
Simon JK, Staerke NB, Hemming-Harlo M, et al. Lot-to-lot consistency, safety, tolerability, and
immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A
randomized phase 3 trial (PNEU-TRUE). Vaccine 2022; 40(9): 1342-51.
112.
Stacey HL, Rosen J, Peterson JT, et al. Safety and immunogenicity of 15-valent pneumococcal
conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother 2019;
15(3): 530-9.
113.
Hammitt LL, Quinn D, Janczewska E, et al. Immunogenicity, Safety, and Tolerability of V114, a 15-
Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without
Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infect Dis
2022; 9(3): ofab605.
114.
Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-
40
MSD 株式会社. 添付文書 15 価肺炎球菌結合型ワクチン「バクニュバンス®水性懸濁注シリンジ」.
2024.
100.
ファイザー株式会社. 添付文書プレベナー20 水性懸濁注. 2024.
101.
Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-
polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9(3): 213-20.
102.
Papadatou I, Tzovara I, Licciardi PV. The Role of Serotype-Specific Immunological Memory in
Pneumococcal Vaccination: Current Knowledge and Future Prospects. Vaccines (Basel) 2019; 7(1).
103.
森野紗衣子, 神谷元, 常彬, 明田幸宏. 今後期待される新規肺炎球菌ワクチン. IASR 2023.
104.
Klugman KP. Vaccines. 7th ed. Philadelphia: Saunders; 2018.
105.
独立行政法人医薬品医療機器総合機構. ニューモバックス NP 審議結果報告書. 2006.
https://www.pmda.go.jp/drugs/2006/P200600040/63015300_21800AMY10131_A100_1.pdf (accessed
2025/1/20).
106.
独立行政法人医薬品医療機器総合機構. 沈降 15 価肺炎球菌結合型ワクチン（無毒性変異ジフテリア
毒素結合体）審議結果報告書. 2023.
https://www.pmda.go.jp/drugs/2023/P20230606001/170050000_30400AMX00410_A100_1.pdf (accessed
2025/1/20).
107.
独立行政法人医薬品医療機器総合機構. プレベナー20 審議結果報告書. 2024.
https://www.pmda.go.jp/drugs/2024/P20240829003/672212000_30600AMX00115_A100_2.pdf (accessed
2025/1/20).
108.
Ermlich SJ, Andrews CP, Folkerth S, et al. Safety and immunogenicity of 15-valent pneumococcal
conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age. Vaccine 2018; 36(45): 6875-82.
109.
Peterson JT, Stacey HL, MacNair JE, et al. Safety and immunogenicity of 15-valent pneumococcal
conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously
vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother 2019; 15(3): 540-8.
110.
Platt HL, Cardona JF, Haranaka M, et al. A phase 3 trial of safety, tolerability, and immunogenicity of
V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in
adults 50 years of age and older (PNEU-AGE). Vaccine 2022; 40(1): 162-72.
111.
Simon JK, Staerke NB, Hemming-Harlo M, et al. Lot-to-lot consistency, safety, tolerability, and
immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A
randomized phase 3 trial (PNEU-TRUE). Vaccine 2022; 40(9): 1342-51.
112.
Stacey HL, Rosen J, Peterson JT, et al. Safety and immunogenicity of 15-valent pneumococcal
conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother 2019;
15(3): 530-9.
113.
Hammitt LL, Quinn D, Janczewska E, et al. Immunogenicity, Safety, and Tolerability of V114, a 15-
Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without
Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infect Dis
2022; 9(3): ofab605.
114.
Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-
40